Financing led by LongRiver Investments with participation by new and existing global investment funds

由新的和现有的全球投资基金参与的LongRiver投资主导的融资

Rona will use proceeds to progress leading metabolic siRNA pipeline programs into global development and expand extra-hepatic delivery platform in CNS and beyond

Rona将利用收益将领先的代谢siRNA管道项目推进全球开发，并在中枢神经系统及其他领域扩展肝外递送平台

SHANGHAI, July 19, 2024 /PRNewswire/ -- Rona Therapeutics, a clinical stage pioneering platform company in nucleic acid drug research and development, today announced the completion of $35 Million Series A+ financing. This round was led by LongRiver Investments, with participation from investors including Zhaode Investment, BioTrack Capital, Zhongqi Capital and Lilly Asia Ventures..

上海，2024年7月19日/PRNewswire/--Rona Therapeutics，一家核酸药物研发的临床阶段先驱平台公司，今天宣布完成3500万美元的a+系列融资。本轮投资由龙江投资牵头，投资者包括昭德投资、生物科技资本、中旗资本和礼来亚洲投资。。

LongRiver Investments will join the board of Rona in connection with the Series A+ financing, commented, 'Rona Therapeutics has successfully brought two best-in-class siRNA metabolic programs into global development and demonstrated differentiated clinical data and platform value. We are impressed by the progress Rona has made in developing innovative siRNA pipeline and expanding into extrahepatic delivery in CNS and beyond.

LongRiver Investments将加入Rona董事会，参与A+系列融资，评论道，“Rona Therapeutics已成功将两个一流的siRNA代谢项目带入全球发展，并展示了不同的临床数据和平台价值。Rona在开发创新的siRNA管道并扩展到中枢神经系统及其他领域的肝外递送方面取得的进展给我们留下了深刻印象。

We look forward to partnering with Rona team to unlock potential of RNA medicine as transformative therapies to patients globally.'.

我们期待着与Rona团队合作，释放RNA医学作为全球患者转化疗法的潜力。”。

Ms. Stella SHI, CEO and Founder of Rona Therapeutics, commented, 'We are thrilled to welcome LongRiver Investments and our other new investors as we progress more best-in-class and first-in-class siRNA programs into global development and catalyzing potential business development opportunities. Rona Therapeutics remains committed to pushing boundaries of RNA medicine in metabolic, obesity, renal and neuro degenerative diseases with Rona's proprietary RNA platform.'.

Rona Therapeutics首席执行官兼创始人Stella SHI女士评论道，“我们很高兴欢迎LongRiver Investments和我们的其他新投资者，因为我们在全球发展中取得了更多一流的siRNA项目，并催化了潜在的业务发展机会。Rona Therapeutics仍然致力于利用Rona专有的RNA平台推动RNA医学在代谢，肥胖，肾脏和神经退行性疾病中的界限。”。

Rona is advancing a pipeline of best and first-in-class siRNA programs generated from next generation siRNA platform. The company's first program RN0191, a best-in-class PCSK9 siRNA program, has completed Australia and China Ph1 clinical studies and ready for Ph2 clinical development for hypercholesterolemia.

Rona正在推进由下一代siRNA平台生成的最佳和一流siRNA程序的管道。该公司的第一个项目RN0191是一流的PCSK9 siRNA项目，已经完成了澳大利亚和中国的Ph1临床研究，并为高胆固醇血症的Ph2临床开发做好了准备。

RN0361 is the company's second program to enter clinic in 2024Q2 for hypertriglyceridemia. The company is also advancing innovative pipeline at IND enabling stage for kidney disease, obesity and cardiometabolic diseases..

RN0361是该公司第二个于2024Q2进入诊所治疗高甘油三酯血症的项目。该公司还在为肾脏疾病、肥胖症和心脏代谢疾病的IND启用阶段推进创新管道。。

About Rona TherapeuticsRona Therapeutics is a global leader in nucleic acid innovative drug platform company, specializing in the treatment of metabolic diseases and CNS degenerative diseases. Rona Therapeutics is always committed to developing the best and first-in-class siRNA drugs, and has unique differentiation and innovation in its liver-targeted metabolism-related pipeline products in cardiovascular diseases, MASH, obesity, and kidney diseases.

关于Rona Therapeutics Rona Therapeutics是核酸创新药物平台公司的全球领导者，专门治疗代谢性疾病和中枢神经系统退行性疾病。Rona Therapeutics始终致力于开发最佳和一流的siRNA药物，并且在心血管疾病，糖化，肥胖和肾脏疾病的肝脏靶向代谢相关管道产品中具有独特的差异和创新。

In addition, Rona Therapeutics is focusing on the potential of extra-hepatic nucleic acid delivery in CNS degenerative diseases and has successfully established a proprietary extra-hepatic delivery platform to treat a range of complex diseases, such as ALS, Alzheimer's disease, etc. which are difficult to treat with traditional drug therapies..

此外，Rona Therapeutics专注于肝外核酸递送在中枢神经系统退行性疾病中的潜力，并成功建立了专有的肝外递送平台，用于治疗一系列复杂疾病，如ALS，阿尔茨海默氏病等。传统药物疗法难以治疗。。

About LongRiver InvestmentsLongRiver Investments is a forward-thinking venture capital firm dedicated to empowering entrepreneurs and driving technological and industrial advancements. With a robust investment strategy and a commitment to excellence, LongRiver Investments aims to deliver superior returns to its investors while making a positive impact on the global market..

关于LongRiver InvestmentsLongRiver Investments是一家具有前瞻性的风险投资公司，致力于赋予企业家权力，推动技术和产业进步。凭借稳健的投资策略和卓越的承诺，LongRiver Investments旨在为投资者提供优异的回报，同时对全球市场产生积极影响。。

For Further information,Please visit: www.ronatherapeutics.com or contact: BD@ronatherapeutics.com

欲了解更多信息，请访问：www.ronatherapeutics.com或联系：BD@ronatherapeutics.com

SOURCE Rona Therapeutics

来源Rona Therapeutics